Researchers found that by December 2023, more than 1 in 3 of the medications being started for type 2 diabetes treatment were GLP-1RA-based medications.

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

People taking GLP-1s consumed less processed food, although they still craved it. As a growing number of people using ...

When it comes to managing weight loss and type 2 diabetes with medications, research shows that it's out with the old and in with the new.

When it comes to managing weight loss and type 2 diabetes with medications, research shows that it's out with the old and in ...

Pfizer is reversing course on developing a weight-loss pill after a patient in its trial suffered what's believed to be drug-induced liver injury.

It's probably safe to say that weight-loss drugs aren't going anywhere any time soon. According to the most recent data, six percent of American adults, or roughly 16 million people, take such ...

Danuglipron was the latest drug investors were hinging hope on to enter the obesity market.

The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a ...

In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body ...

People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.